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This investment case outlines why and how an 
investment of US$17 million over 4 years can:
•	 reduce adverse outcomes of syphilis in 
pregnancy by 2015 through intensified support 
to 12 high-burden countries, and develop a 
stronger global network to eliminate MTCT of 
syphilis in other countries;
•	 strengthen sexual and reproductive health 
services, as well as maternal and child health 
services, to ensure dual elimination of MTCT of 
HIV and syphilis;
•	 improve collaboration among, and capacity 
of, stakeholders engaged in activities aimed at 
reducing the overall burden of adult syphilis.
Through a series of national, regional and 
international consultations, it is clear that a number 
of countries are committed to syphilis elimination. 
These countries have established ANC, prevention 
of MTCT of HIV, and other programmes, which are 
funded through various sources. Countries have 
asked for technical support to prioritize and scale 
up interventions for MTCT of syphilis in a way 
that builds upon existing investments in maternal 
and child health services. The investment case 
is not intended to provide resources for routine 
programme management and operations at the 
country level, but rather to assist countries in 
identifying how to incorporate antenatal syphilis 
testing and treatment into routine national health 
plans and expenditure for ANC.
Despite its devastating impact, MTCT of syphilis 
is preventable and curable. And now – more than 
ever before – is the right time to address it with a 
coordinated, strategic global initiative. Investment 
in the elimination of MTCT of syphilis will contribute 
significantly to improved maternal and child health 
around the world, including achievement of MDGs 
4, 5 and 6, while also strengthening underlying 
health systems.
Executive summary
Nearly 1.5 million pregnant women are infected 
with probable active syphilis each year, and 
approximately half of infected pregnant women who 
are untreated, will experience adverse outcomes 
due to syphilis, such as early fetal loss and stillbirth, 
neonatal death, low-birth-weight infants, and infants 
with clinical evidence of infection. It is estimated that 
in 2008, syphilis in pregnancy contributed to 305 000 
stillbirths and fetal and neonatal deaths, and an 
additional 215 000 infants at increased risk of dying 
from low birth weight, prematurity or complications 
of infection related to syphilis.
Mother-to-child transmission (MTCT) of syphilis 
(commonly referred to as “congenital syphilis”) is 
relatively simple to eliminate and it is inexpensive 
to detect and treat, making it a possible “easy win” 
in terms of cost, feasibility and speed of scale-up. 
Investing in screening and treatment for syphilis 
in pregnant women ranks as one of the most 
cost-effective antenatal interventions. Screening 
all pregnant women, using simple and low-cost 
technologies, is feasible, even in low-resource 
settings. Syphilis is easily cured with penicillin, and 
MTCT of syphilis is easily prevented when pregnant 
mothers with syphilis infection are identified 
early and treated promptly. Penicillin is off patent, 
widely available, on the World Health Organization 
(WHO) list of essential medicines and, above all, 
inexpensive.
Moreover, a number of factors make this the ideal 
time to invest, specifically: the strong political 
will on the part of many governments in high-
burden countries to support the Global strategy 
for women’s and children’s health; the resources 
and attention being devoted to achieving the 
Millennium Development Goals (MDGs), particularly 
HIV, reproductive, maternal, newborn and child 
health objectives (MDGs 4, 5 and 6); the push for 
dual elimination of MTCT of HIV and syphilis; the 
increased availability and use of antenatal care (ANC) 
in many countries; and technological advances in 
screening for syphilis in low-resource settings.
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This document uses the term mother-to-child 
transmission (MTCT) of syphilis throughout, 
but it should be noted that most of the related 
literature to date uses the term congenital 
syphilis. The term MTCT is preferred, as it 
better reflects the range of adverse outcomes 
that occur when syphilis is transmitted from 
mother to child. MTCT of syphilis is any adverse 
outcome in a fetus or neonate associated 
with syphilis infection in a pregnant woman. 
Adverse outcomes include early fetal loss, 
stillbirth, neonatal death, prematurity, low 
birth weight and clinical evidence of syphilis in 
a neonate.
Untreated maternal syphilis results in MTCT of 
syphilis (see text box) in over half of affected 
pregnancies (see Table 1.1). A recent meta-analysis 
of syphilis-associated pregnancy outcomes found a 
profound impact: stillbirth and late fetal loss in 21% 
and neonatal death in 9% of untreated infections (7). 
Additionally, untreated maternal syphilis contributes 
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Table 1.1 
Estimated proportion of adverse outcomes in untreated pregnancies affected by syphilis, and number 
of adverse outcomes in 2008 taking into account existing servicesa
Outcome Estimated %  
of adverse outcomes in 
untreated pregnancies 
affected by syphilis
Estimated number of 
adverse outcomes in 2008 
Early fetal loss/stillbirth 21 215 000
Neonatal death  9  90 000
Prematurity or low birth weight  6  65 000
Clinical evidence of syphilis in newborn 16  150 000
Any adverse outcome  52  520 000
a Adverse outcomes estimates = % of pregnancies affected in syphilis seropositive women minus the % of pregnancies affected in 
syphilis seronegative women. This methodology thus accounts for background morbidity and mortality not attributable to syphilis.
1.1 Mother-to-child transmission of 
syphilis: a continuing public health 
burden
An estimated 11 million people acquire new syphilis 
infections annually (1). This is despite the fact that a 
successful test for syphilis has been available since 
the early 1900s and effective treatment (penicillin) 
has been widely available since the 1940s.
In 2009, there were approximately 2.6 million 
stillbirths and an additional 3.1 million infants died 
with in the first month of life (2, 3). In 2004, the 
World Health Organization (WHO) global burden of 
disease estimate of deaths due to syphilis among 
children aged 0–4 years was approximately 64 000 
deaths, or 0.6% of all deaths in children aged under 
5 years (4). However, it is widely felt that syphilis 
is underdiagnosed as a cause of death in death 
registries and verbal autopsies, and estimates in 
some developing countries have suggested that 
mother-to-child transmission (MTCT) of syphilis 
contributes to up to one quarter of all stillbirths and 
11% of neonatal deaths (4–6).
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sufficient laboratory capacity and minimal quality-
control processes. With a combination of these 
two diagnostic options, programmes can achieve 
universal access to syphilis screening in pregnant 
women. If syphilis is diagnosed early and treated 
promptly, penicillin is highly effective in treating 
maternal infection and preventing MTCT of syphilis 
(11). Penicillin is off patent, widely available, on the 
WHO list of essential medicines (12) and, above 
all, inexpensive. Moreover, Treponema pallidum, 
the bacterium causing syphilis, has not developed 
resistance to penicillin.
1.3 Why now is the time to invest 
in elimination of mother-to-child 
transmission of syphilis
More than ever before, elimination of MTCT of 
syphilis as a public health problem is feasible, 
achievable and affordable.
The Millennium Development Goal  
“window of opportunity”
As we near the 2015 deadline for achieving 
the Millennium Development Goals (MDGs), 
there is increased global commitment and 
attention to improving child and maternal health 
(MDGs 4 and 5). This paves the way for tackling 
MTCT of syphilis as an important contributor to 
maternal and infant morbidity and mortality.
Elimination of MTCT of syphilis will contribute 
to MDGs 4 (reduce child mortality), 5 (improve 
maternal health) and 6 (combat HIV/AIDS, 
malaria and other diseases).
Addressing MTCT of syphilis through an initiative 
that strengthens ANC services as well as existing 
infrastructure and programmes can contribute to 
reductions in other preventable infections affecting 
pregnancy, including perinatal malaria, maternal 
and neonatal tetanus, and HIV transmission to 
neonates, and can improve maternal health. This 
will bolster efforts to achieve MDGs 4, 5 and 6 
(combat HIV/AIDS, malaria and other diseases), as 
highlighted in the 2009 United Nations (UN) MDG 
report (13).
to serious neonatal complications such as 
premature and low-birth-weight infants (6%) and 
infants with clinical evidence of syphilis (16%) – 
who are then at higher risk of ill health. Estimates 
for 2008 suggest that globally there are nearly 
1.5 million pregnant women infected with probable 
active syphilis each year (8). Although there is wide 
variation in antenatal care (ANC) practices globally, 
the vast majority of pregnant women with syphilis 
are not identified and treated early enough to avoid 
the adverse effects of infection on their pregnancy. 
Thus, assuming that 30–70% (depending on region) 
of all pregnant women with syphilis were tested 
and treated early enough to avert an adverse 
outcome, in 2008 there were an estimated 520 000 
pregnancies and neonates adversely affected by 
syphilis, including 215 000 early fetal losses and 
stillbirths and 90 000 neonatal deaths.
1.2 Addressing syphilis in pregnant 
women: a feasible solution
Adverse pregnancy outcomes caused by untreated 
maternal syphilis are preventable and curable, and 
interventions to improve screening and treatment 
for syphilis in pregnancy can substantially reduce 
the current global burden of preventable perinatal 
mortality and morbidity (9) Detection and treatment 
of syphilis has been identified as being one of the 
most effective and cost-effective interventions 
to prevent stillbirths and neonatal deaths (10). 
Screening all pregnant women, using simple and 
low-cost technologies, is feasible, even in low-
resource settings.
All pregnant women should be tested for 
syphilis, not just those perceived as being 
“high risk”.
New point-of-care tests, which can use whole-blood 
samples from a finger prick, provide results and 
allow for treatment at a single visit. They can be 
used in all health-care settings, even in the face of 
limited electricity, refrigeration or skilled laboratory 
staff. Existing tests (rapid plasma reagin (RPR) 
or venereal disease research laboratory (VDRL)) 
can also be used successfully in settings with 
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conditions during pregnancy. Through the initiative 
outlined in this document, maternal health will 
be improved as a result of earlier ANC and fewer 
spontaneous abortions and stillbirths. In addition, 
the simultaneous implementation of interventions 
to eliminate MTCT of syphilis, and efforts to control 
sexually transmitted infections (STIs) in the general 
adult population, will also reduce the incidence and 
prevalence of syphilis in pregnant women.
MDG 6: combat HIV/AIDS, malaria and other 
diseases
It is estimated that women account for about half 
of all people living with HIV infection, and that 
the vast majority of HIV-infected women live in 
developing countries. Given the common mode of 
sexual transmission, coinfection of HIV and syphilis 
is not uncommon. Syphilis infection is a recognized 
cofactor for increased risk of HIV transmission and 
acquisition, and maternal syphilis infection has even 
been associated with increased risk of MTCT of HIV 
(15, 16).
WHO recognizes that HIV services should be 
integrated within a package of core interventions for 
maternal, newborn and child health that includes 
MDG 4: reduce child mortality
Infant and child mortality have declined globally, 
but the pace of progress is uneven. In 2010, an 
estimated 8 million children died before their 
fifth birthday – mainly from preventable causes. 
MTCT of syphilis is a preventable cause of low birth 
weight, neonatal death, stillbirth and congenital 
infection (3). The UN MDG report states that “many 
countries, particularly in sub-Saharan Africa and 
southern Asia, have made little or no progress at all 
[towards MDG 4]” (13) (see Box 1.1). An emphasis 
on strengthening health systems to provide ANC, 
which includes screening for MTCT of syphilis, will 
help to address this public health tragedy.
MDG 5: improve maternal health
ANC is a core component of comprehensive 
maternal health care. The UN MDG report 
emphasizes that “many health problems among 
pregnant women are preventable, detectable 
or treatable through visits with trained health 
workers before birth” (13). In all regions, progress 
has been made on ensuring that more women 
reach and receive at least one ANC visit in their 
pregnancy – thus providing more opportunities 
for women to be screened for syphilis and other 
Box 1.1 
Avoiding HIV but dying of syphilis
An HIV-positive mother in Haiti successfully completes therapy for prevention of mother-to-child-
transmission (PMTCT) of HIV, but her baby dies at 3 weeks from congenital syphilis [mother-to-child 
transmission of syphilis]. This is not an isolated case.
Large investments in PMTCT of HIV have been one of the big successes of recent years. But too many of 
the babies born HIV free tragically die of syphilis. This is despite the fact that it is feasible and cheap to 
add screening for syphilis to existing antenatal and PMTCT programmes.
Even in countries with clear policy recommendations on syphilis screening, congenital syphilis still 
poses a major threat to both women and infants. For example, only about one third of women attend-
ing antenatal clinics in 22 sub-Saharan African countries were reported to have been tested for syphilis, 
despite 17 of these countries having explicit policy recommendations mandating syphilis screening. 
This shows a clear disconnect between policy and implementation.
There is an opportunity for policy-makers and the donor community to recognize the importance of 
integration of programmes at the local level, and to capitalize on new opportunities to enhance health 
systems.
A concerted effort can avert the tragedy of babies avoiding HIV but dying of syphilis, and help to real-
ize the goal to reduce childhood mortality.
 
Source: Peeling R et al. Avoiding HIV and dying of syphilis. The Lancet, 2004, 364:1561–1563 (14).
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More availability and utilization of antenatal 
care than ever before
The relatively high utilization of ANC by pregnant 
women in many countries makes this service 
an ideal venue to implement population-based 
interventions. Although women often delay seeking 
care until later in pregnancy, an estimated 82% of 
pregnant women have at least one ANC visit (24).
An important component of the initiative proposed 
in this investment case will be to promote 
sufficiently early ANC, which maximizes the benefits 
of maternal syphilis screening when universally 
provided to women at low or no cost, as part of 
an integrated service package of proven-effective 
antenatal interventions. Early ANC also improves 
the effectiveness of other antenatal interventions, 
including prevention of HIV and malaria.
Important technological advances
Existing screening for syphilis (i.e. RPR testing) is 
simple and cheap, but requires a basic laboratory 
capacity and quality control that may not be 
available at many antenatal facilities, particularly in 
remote settings or in resource-poor settings with 
limited infrastructure. However, syphilis screening 
has evolved over the past 10 years. On-site 
diagnosis of syphilis and prompt treatment of 
women who screen positive is increasingly possible, 
even in remote settings, with rapid point-of-care 
diagnostics. These new diagnostics allow syphilis-
infected women to be diagnosed and treated in a 
single antenatal visit. Extensive research has helped 
greatly in our understanding of more effective 
diagnostic tools, algorithms and approaches in 
specific settings, and has ensured availability of 
high-performing point-of-care syphilis tests to low- 
and middle-income countries at affordable prices 
(i.e. at less than US$1 per test).
1.4 Why the problem persists
In theory, it is easy and cheap to prevent and 
treat MTCT of syphilis. In practice, however, there 
have been a number of barriers to elimination. 
Chief among these is a general lack of awareness 
of the true impact of MTCT of syphilis and the 
extent of the problem. Without diagnostic testing, 
syphilis screening and care (17). Systematic screening 
of women for syphilis in programmes for PMTCT of 
HIV will allow mothers and infants to be tested and, 
where necessary, treated for both HIV infection and 
syphilis, thereby reducing fetal and infant deaths. 
Treating maternal syphilis infections also improves 
maternal and neonatal health. Moreover, the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) 
recognizes testing and treatment of syphilis in 
pregnant women as an indicator of quality ANC 
services in the context of HIV prevention (18).
Global momentum to eliminate new HIV 
infections among children
The global call to eliminate new HIV infections 
among children by 2015 and keep their mothers 
alive specifically notes the importance of HIV 
programmes working together with maternal, 
newborn and child health programmes to lead to 
improved health outcomes (17, 19). Three WHO 
regions (Region of the Americas, South-East Asia 
Region, and Western Pacific Region) have launched 
elimination of MTCT of HIV as a dual elimination 
initiative with MTCT of syphilis, and the African 
Region includes elimination of MTCT of syphilis 
within its strategy for elimination of MTCT of HIV 
(20–22). Such dual-elimination initiatives strive to 
promote synergies for overall strengthening of the 
perinatal health-system platform.
Elimination of mother-to-child transmission 
of syphilis supports the global strategy for 
women’s and children’s health
With just a short amount of time left to achieve 
the MDGs, the UN Secretary-General launched the 
Global strategy for women’s and children’s health 
(23). This strategy calls for all partners to unite to 
enhance financing, strengthen policy and improve 
service delivery of proven interventions. As a 
result, many countries have committed to improve 
coordination around maternal and neonatal 
health issues and create platforms for integration. 
Bringing ministries of health and partners together 
to provide universal coverage of antenatal syphilis 
screening, and ensuring treatment of all pregnant 
women with syphilis, is a specific example of an 
activity called for within the global strategy.
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1.5 The strong economic case for 
syphilis elimination
Economic costs of mother-to-child 
transmission of syphilis
The direct medical costs of MTCT of syphilis 
are substantial, because of the infection’s high 
prevalence and high rate of complications. 
However, the true economic burden of any disease, 
including syphilis, includes more than just direct 
medical costs. It involves indirect costs, such as lost 
productivity, and other non-medical costs, such as 
special educational needs and the emotional impact 
of having a disabled child, which are extremely 
difficult to quantify.
Although the full economic cost of MTCT of syphilis 
has not been definitively determined, available 
estimates of the direct medical costs can provide a 
glimpse of the true cost to individuals, families and 
syphilis-associated fetal loss and stillbirth, neonatal 
deaths and premature births are not recognized as 
being caused by syphilis or as being preventable. 
Lack of awareness about the true toll of maternal 
syphilis is a significant barrier at all levels – in 
communities, among service providers and 
programme managers, and among policy-makers 
and decision-makers (25). In many countries, a 
lack of clarity regarding roles, responsibilities and 
accountability for measures to control MTCT of 
syphilis is a problem, since efforts involve both STI 
and maternal and child health (MCH) programmes. 
In addition, many existing ANC programmes do not 
have the information, training and technology they 
need to incorporate maternal syphilis screening and 
treatment into their health-care systems.
Other key barriers are outlined in Table 1.2.
Table 1.2 
Barriers to the elimination of mother-to-child transmission of syphilis
Setting Barriers
In local communities •	 The problem is not seen as important
•	 Women do not seek ANC early enough or at all, or do not seek care 
from trained providers
•	 Stigma associated with STIs
•	 Costs associated with detection and treatment, whether direct, 
indirect, opportunity related or stigma related 
Among health-care service 
providers
•	 Lack of awareness of or training in the appropriate intervention
•	 Lack of commodities appropriate to the setting
•	 Insufficient logistical support for the intervention
•	 No financial incentives to screen for syphilis (especially among private 
providers)
Among programme managers •	 Syphilis accorded a low priority compared with other health problems
•	 Lack of resources for effective interventions
•	 Lack of clarity regarding roles, responsibilities and accountability
•	 Poor planning, coordination and monitoring of programmes
Among policy-makers and 
decision-makers
•	 Lack of awareness of true disease burden
•	 Lack of awareness of the cost effectiveness of the intervention
•	 Little external pressure to adopt or implement policies
•	 Few apparent political rewards for action
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be prevented or treated through improving current 
ANC programmes. For each ill-health outcome, the 
economic cost and the health burden (in actual 
numbers of cases, deaths and DALYs) are presented. 
These estimates are based on current levels of 
programme coverage – which is higher for some 
programmes (e.g. neonatal tetanus) than others (e.g. 
MTCT of syphilis). Because different conditions cause 
different types of outcomes, and estimates are not 
available for all potential outcomes (e.g. stillbirth 
associated with HIV), death estimates are not 
directly comparable.
Cost effectiveness of syphilis-elimination 
programmes
We have conducted ananalysis of the additional 
cost, health impact and cost-effectiveness of 
implementing syphilis programmes in existing ANC 
screening programmes in eight different country 
case scenarios, which vary in terms of syphilis 
testing and treatment coverage (high (70%) or low 
(20%)), syphilis ANC prevalence (high (3%) or low 
(0.5%)), and country cost of health services (high 
or low). For each of the eight different country 
scenarios, the cost analysis assesses the cost of 
the intervention (i.e. implementing testing and 
treatment of syphilis in pregnancy), while the 
health-impact analysis estimates the health benefits 
of the intervention in terms of DALYs averted. 
health systems. For example, in the United States 
of America (USA), the hospital cost per newborn 
infant with congenital syphilis (MTCT of syphilis) 
was estimated to be almost US$5000 higher than 
the cost per uninfected infant (26). In South Africa, 
hospital-based treatment of congenital syphilis 
(MTCT of syphilis) was estimated at US$638 per 
case (27). Globally, the annual direct medical costs 
of addressing the adverse outcomes associated with 
syphilis in pregnant women are calculated to be 
US$309 million (see Table 1.3).
MTCT of syphilis, tetanus, malaria, 
hypertension and HIV are all important 
contributors to disease burden in pregnant 
women.
Although the direct medical costs of MTCT of 
syphilis are estimated to be lower than those of 
some other perinatal infections, such as vertically 
transmitted HIV (estimated to be US$3520 million), 
the current global burden of disease attributable to 
MTCT of syphilis as measured in disability-adjusted 
years (DALYs) is enormous, at approximately 
3.6 million. A DALY is a time-based measure of the 
burden of disease that combines years of life lost 
due to premature mortality with the time lived in 
a state of less than full health. Table 1.3 outlines 
several conditions affecting pregnancy that could 
Table 1.3 
Disease burden in pregnant women, associated perinatal deaths, DALYs and direct medical costs for 
syphilis, tetanus, malaria, hypertension and HIV
Clinical cases Deaths DALYs Direct medical 
costs (US$)
Syphilis 1 360 000 pregnant 
women (8)
305 000 fetal, stillbirth, 
neonatal (8)
3.6 milliona 309 millionb
Tetanus 187 000 children 
aged 0–4 years (28)
187 000 children aged 
0–4 yearsc (27)
5.1 million (28) No data available
Malaria No data available 563 300 children aged 
<5 years (29)
No data available No data available
Hypertension No data available 71 000 maternal (28) 1.9 million (28) No data available
HIV 440 000 new infec-
tions in children (30)
440 000 new infections 
in children
6.2 million (31)  3520 million (31) 
a DALYS for syphilis also include low-birth-weight and syphilis-infected infants. 
b Assumes a 50:50 share of less- and more-expensive country settings. 
c Tetanus deaths include the age group 0–4 years (excludes stillbirths); expert opinion is that 90% of deaths are neonatal.
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gross domestic product per capita in any country, 
the WHO criterion for “very cost effective”.
1.6 Who should invest in the 
elimination of mother-to-child 
transmission of syphilis?
Efforts to improve maternal and child health, and 
specifically to eliminate MTCT of syphilis, can be 
considered to constitute a global public good, 
defined as multicountry policies, programmes 
and initiatives having a positive impact on health 
that extends beyond the borders of any specific 
country (33). However, even with widespread 
consensus around the financial and social benefits 
of procuring a global public good, achieving these 
benefits requires the involvement and commitment 
of a wide range of actors and stakeholders.
•	 Those interested in reducing neonatal and 
infant mortality should invest because 
untreated maternal syphilis contributes to nearly 
a quarter of a million stillbirths each year – an 
especially high proportion of all stillbirths in 
developing countries. In addition, in 2008, MTCT 
of syphilis contributed to approximately 90 000 
neonatal deaths, 65 000 low-birth-weight or 
premature babies and 150 000 babies born with 
syphilis infection – almost all preventable.
The cost-effectiveness analysis combines this 
information into an estimate of the “cost per DALY 
averted”, taking into account the medical costs 
saved by the intervention. An intervention is said to 
be “cost-saving” if it pays for itself in terms of offset 
medical costs. In such instances, the cost per DALY 
averted is <US$0. The key inputs and results are 
presented in Table 1.4 for each of the eight different 
country case scenarios, and described in greater 
detail in Appendix 1. Although the data presented 
are calculated as a ratio per 1 million pregnancies, 
the results should scale (i.e. the costs and the health 
outcomes would change similarly for smaller or 
larger populations), thus leaving the cost per DALY 
unchanged for countries of different sizes.
The costs of controlling MTCT of syphilis are 
outweighed by the money saved in nearly all 
scenarios.
We found that controlling MTCT of syphilis would 
be a “cost-saving” intervention in four of the eight 
country scenarios examined – i.e. the intervention 
will “pay for itself” in offset medical costs. In the 
other four scenarios, the cost per DALY averted is 
between US$20 and US$100, far below the annual 
Table 1.4 
Estimated net cost (in US$) over 4 years, number of DALYs averted over 4 years and cost per DALY 
averted for eight country scenarios varying by burden of disease, syphilis testing and treatment 
coverage, and health-care costsa
Country 
scenario
Prevalence 
of syphilis 
in pregnant 
women
Proportion of 
all pregnant 
women 
tested and 
treated
Health-
care cost 
structure
Net cost (savings) of 
intervention (4 years) 
(cost of intervention 
minus disease costs 
averted), US$
Number 
of DALYs 
averted  
(4 years)
Cost per 
DALY 
averted, 
US$
A High Low Low (1 943 017) 106 042 Cost savingb
B High Low High (12 261 250) 106 042 Cost saving
C High High Low (765 563) 39 155 Cost saving
D High High High (4 587 778) 39 155 Cost saving
E Low Low Low 1 736 807 17 678 98.25 
F Low Low High 543 472 17 678 30.74 
G Low High Low 593 188 6527 90.88 
H Low High High 140 282 6527 21.49 
a Classifications used for this exercise are: prevalence of syphilis = high (3%) or low (0.5%), proportion of all pregnant women 
tested and treated = high (70%) or low (20%), health-care cost structure = high (1) or low (0.25), based on WHO CHOICE (CHoosing 
Interventions that are Cost Effective) data (32). 
b The cost per DALY averted ratio is not calculated when the intervention is “cost saving” – i.e. reduces DALYs and saves money.
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1.7 How much and what sort of 
investment is needed?
We are seeking an investment of US$17 million 
over 4 years (see budget in Appendix 2), which will 
facilitate the implementation of the initiative to 
eliminate MTCT of syphilis in up to 12 “intensified 
support” countries (see Fig. 1.1). We estimate that 
this level of implementation will reduce cases of 
MTCT of syphilis by 80% in these countries by the 
end of 2015. In 2008, the estimated burden of 
disease in the proposed 12 countries accounted 
for 33% of the global burden of pregnancies and 
neonates affected by syphilis. The funding will 
also enable WHO to provide technical support at a 
global and regional level to other countries working 
towards the elimination of MTCT of syphilis (“general 
support” countries).
•	 Those interested in promoting maternal health 
should invest because improving screening 
in ANC is an opportunity to identify women at 
risk of pregnancy complications and adverse 
outcomes of pregnancy.
•	 Those interested in reducing STIs should invest 
because this initiative will reduce the overall 
burden of STIs. It will also increase countries’ 
abilities to identify pregnant women with 
syphilis, which can facilitate partner notification, 
thus strengthening overall syphilis control in 
high-burden countries.
•	 Those interested in HIV should invest because 
integration of syphilis screening with HIV 
screening in pregnancy is a low-cost intervention 
that contributes to dual elimination of MTCT of 
HIV and syphilis and makes HIV services more 
comprehensive.
•	 Those interested in strengthening health 
services to deliver integrated sexual and 
reproductive health care should invest because 
this initiative represents a vital step towards 
integration of STI prevention and care into 
maternal health services.
Uruguay   1.3%
Honduras  1.5%
Ghana  3.4%
Madagascar  6.0%
Central African Republic 
10.0%
United Republic 
of Tanzania  2.8%
Indonesia  1.2%
Papua New Guinea
4.8%
Myanmar  0.7%
China  0.4%
Mozambique 5.7%Zambia 5.3%
Fig. 1.1 
Reported syphilis prevalence for 2010 (2009 for Indonesia) in intensified support countries for the 
investment case for eliminating mother-to-child transmission of syphilisa
a Source: Data for Papua New Guinea are from the National Department of Health, STI, HIV and AIDS Surveillance Unit: The 2010 STI, HIV 
and AIDS Annual Surveillance Report.  Data for Indonesia available at: http://www.who.int/hiv/pub/2010progressreport/en/index.html.  
Data for all other countries available at: http://www.who.int/hiv/pub/progress_report2011/en/. 
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•	 reduce adverse outcomes of pregnancy due to 
MTCT of syphilis through intensified support 
in 12 focus countries by 2015: achieved by 
scaling up early maternal syphilis screening 
for all pregnant women and ensuring prompt 
treatment for women with positive tests;
•	 strengthen sexual and reproductive health 
services, including family planning, maternal 
and child health services: this will involve 
ensuring that activities aimed at elimination 
of MTCT of syphilis are integrated into existing 
health systems, commodities distribution and 
monitoring and evaluation systems;
•	 promote collaboration among different 
stakeholders working to reduce the overall 
the burden of syphilis: this will include building 
on synergies and forging partnerships among 
different groups and agencies that address adult 
syphilis.
To realize these objectives, specific activities will be 
carried out in 12 intensified support countries and at 
regional and global levels. In addition, the support 
network created by the investment case will provide 
general support to other high-burden countries 
requesting technical assistance to eliminate MTCT of 
syphilis.
2.1 Choosing 12 intensified support 
countries
The 12 intensified support countries were selected 
by the WHO regional offices from among those 
countries with available data demonstrating a 
high burden of disease. In addition, selection of 
countries was determined by level of interest and 
commitment to implementation of the 4-year 
plan through improved maternal and child health 
services. The full selection criteria included:
•	 demonstrable burden of syphilis in pregnancy or 
its adverse consequences;
•	 interest in integration of initiative activities into 
existing national maternal and child health 
frameworks;
•	 commitment to attaining high coverage of ANC 
services;
2.  Details of the initiative: objectives, activities and 
stakeholders
The overall goal of the initiative is global elimination 
of MTCT of syphilis as a public health problem (34). 
The specific goals of this elimination effort are to 
prevent transmission of syphilis from mother to 
child through ensuring that:
•	 at least 90% of pregnant women are screened for 
syphilis;
•	 at least 90% of pregnant women who are 
positive for syphilis are treated appropriately.
Given the difficulties in diagnosing and reporting 
MTCT of syphilis consistently throughout the 
world, a specific global target for a case rate 
for MTCT of syphilis has not been set. However, 
countries and regions are encouraged to identify 
country- or region-specific goals and targets 
to measure the impact of elimination efforts. 
The Region of the Americas, South-East Asia 
Region, and Western Pacific Region  have defined 
elimination of congenital syphilis (MTCT of syphilis) 
as corresponding to an incidence of 0.5 cases or 
fewer per 1000 births (including stillbirths) (21, 22). 
However, this specific threshold was established for 
these regions and may not be appropriate for the 
rest of the world.
Elimination can be achieved by strengthening 
reproductive and sexual health programmes to 
ensure:
•	 the unmet need for family planning is met, thus 
helping women to avoid unintended pregnancy;
•	 early ANC, including syphilis screening for all 
pregnant women, and prompt treatment of 
those infected;
•	 treatment of all sexual partners of infected 
women, promotion of condom use during 
pregnancy and counselling of all women on how 
to prevent infection;
•	 all neonates born to syphilis-positive mothers 
are given penicillin as presumptive treatment.
There are three primary objectives for the 
investment case:
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newborn and child health services that support 
elimination of MTCT of syphilis, in addition to 
other perinatal and maternal health outcomes;
3. monitoring and evaluation of interventions 
related to MTCT of syphilis through 
strengthened existing systems, within each of 
the countries as well as at global and regional 
levels.
Activity stream 1: gathering evidence to guide 
best practice
Much about MTCT of syphilis is well understood, 
but additional evidence in certain areas – 
particularly practical operational research – is 
needed to strengthen the implementation and 
effectiveness of country plans for eliminating 
the condition. Proposed research areas are not 
stand-alone activities, but exist to strengthen the 
implementation of feasible, high-quality, cost-
effective and sustainable interventions to eliminate 
MTCT of syphilis.
Table 2.1 outlines some of the areas of research 
necessary to support the implementation and 
evaluation of interventions to eliminate MTCT of 
syphilis, which is a vital element of the initiative. 
Each country has its own need for filling evidence 
gaps; therefore, research priorities will be set locally 
– and may be drawn from this indicative list, or 
from elsewhere. It is expected that countries will 
also leverage additional funds to support evidence 
gathering locally.
Activity stream 2: building capacity for the 
development and implementation of national 
plans
While each country has its own unique issues 
regarding elimination of MTCT of syphilis, this 
initiative will help national health ministries to 
identify the best means to address issues specific 
to their country, and will promote clarification of 
the roles and responsibilities within the context of 
existing programmes.
•	 initiation of collection of indicators for national 
and global monitoring, including some form of 
stillbirth surveillance;
•	 designation of at least one person to coordinate 
and monitor congenital syphilis (MTCT of 
syphilis) activities;
•	 desire by regional offices to strive for subregional 
diversity and representativeness.
All of the countries selected for intensified support 
have made significant investments in establishing 
effective ANC programmes, and their participation 
in the initiative should strengthen these investments 
over the medium and long term.
It is recognized that many of the countries with 
the highest burden of disease may not have data 
available and that data on burden of disease 
change over time. However, other countries will 
receive general support through the network 
established with the funding of the investment 
case, in particular for monitoring and evaluation. In 
addition, once activities in the 12 intensified support 
countries are under way, a phased approach to 
supporting other high-burden countries in future 
phases of the investment case will be discussed and 
developed.
2.2 Activities
While the initiative is designed to bring about a 
major reduction in cases of MTCT of syphilis in 12 
intensified support countries, investment case funds 
are not primarily intended for routine programme 
expenses. Instead, investment case funds are sought 
to provide assistance with integrating syphilis 
interventions into existing programmes, and 
ensuring and sustaining the effectiveness of these 
interventions. To this end, funding for the initiative 
will be devoted to three activity streams:
1. gathering evidence to assess the current 
situation and needs in each country in relation 
to MTCT of syphilis, to determine the most 
effective approach to elimination;
2. building capacity for the development and 
implementation of national plans to scale 
up the coverage and quality of maternal, 
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Table 2.1 
Key research areas for efforts for elimination of mother-to-child transmission of syphilis
Evidence needed Where can evidence be gathered?
Who is at risk of syphilis in pregnancy?
Aim of research – to understand epidemiological and demo-
graphic features associated with the risk of syphilis in pregnancy
Country- and subnational-level re-
search – primary data collection
What is the impact of syphilis in pregnancy?
Aim of research – to further explore the impact of MTCT of syphi-
lis (particularly stillbirths, neonatal and infant deaths) in a wider 
variety of settings (e.g. extent of infant death (>28 days) related 
to maternal syphilis, impact of stillbirth in low-income settings)
Multicountry studies, possibly linking 
to existing national surveys
Modelling studies at global/national 
levels
What are the most effective models for delivering the interven-
tion?
Aim of research – to identify different models for delivering 
syphilis screening and treatment for pregnant women, e.g. how 
to increase early ANC attendance; how to engage communities in 
increasing ANC attendance
Country-level studies of health systems
What are the resource requirements for delivering the inter-
vention?
Aim of research – to quantify levels of resources (human, finan-
cial, logistic, policy) needed to achieve elimination in different 
settings. What additional data are needed to support inclusion 
of MTCT of syphilis as a contributor to infant mortality for major 
global initiatives?
Country-level studies focusing on the 
level of service delivery
How can the effectiveness of screening and treatment be im-
proved?
Aim of research – to maximize the potential of interventions 
(screening and treatment) in different settings. Also, to address 
issues such as the best methods of partner services, timing of 
screening/treatment, algorithms for use of enzyme-linked im-
munoassay tests, increasing availability of penicillin at lower-level 
facilities, etc.
Country-level studies of health systems 
and on the level of service delivery
Monitoring and evaluation issues
Aim of research – to identify feasible and appropriate indicators 
for monitoring and evaluation at multiple levels (e.g. use of still-
birth as an impact measure). How to interpret data with increased 
use of treponemal rapid testing. What are appropriate criteria for 
certification and maintenance of elimination?
Studies at country, regional and global 
levels
What is the evidence for integrated interventions?
Aim of the research – to understand the benefits and risks of in-
tegrated screening efforts (e.g. with PMTCT or malaria prevention 
in pregnancy). What is the field performance of dual HIV/syphilis 
point-of-care tests?
Country-level studies; literature reviews
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to support implementation of the country plans 
(see Appendix 3). The tools and technical support 
provided by the initiative partners can assist 
countries to set their own priorities for syphilis 
elimination and improvement of ANC. The process 
is intended to increase the likelihood that all 
stakeholders will buy into the priorities set for the 
initiative, thereby strengthening sustainability and 
the potential for success.
Intensified support countries will be asked to 
make a commitment to ensuring that their existing 
workforce involved with maternal, newborn and 
child health systems will carry out the country plans 
for the elimination of MTCT of syphilis. Furthermore, 
over the course of the 4 years of funding, we will 
work with intensified support countries to obtain 
future funding or justify the reallocation of existing 
health-care budgets to ensure the sustainability of 
the intervention.
Activity stream 3: monitoring and evaluation
Monitoring and evaluation are critical components 
of the initiative at multiple levels. At national, 
subnational and local levels, the collected data will 
be used to ensure that programmes have sufficient 
coverage and quality to meet the initiative’s 
goal, and that key subpopulations are targeted 
appropriately. It will also serve as vital evidence for 
advocacy and resource mobilization around the 
elimination of MTCT of syphilis, which can ensure 
programme continuity and sustainability.
Intensified support countries will receive technical 
support to develop their own national plans 
through the following processes:
•	 consultations between WHO regional offices and 
country ministries of health to gauge interest in 
each country (in process);
•	 regional-level meetings involving participants 
from interested countries (already held in some 
regions);
•	 country development of plans and strategies 
for elimination of MTCT of syphilis, with global 
and regional support, assistance and capacity 
building, to:
	− strengthen and expand coverage of early 
maternal screening and prompt treatment of 
individuals who test positive;
	− integrate global indicators of elimination 
of MTCT of syphilis into existing maternal, 
newborn and child health monitoring and 
evaluation systems (in process).
Countries are encouraged to identify opportunities 
to develop integrated plans or plans that take 
other programmes into account, such as the dual 
initiatives in the three WHO regions to eliminate 
MTCT of HIV and syphilis (see Section 1.3) (21, 22). 
Once plans have been developed, each country 
will be encouraged and supported to follow a 
step-by-step approach to implementation, such as 
that based on WHO’s programme guidance tool for 
reproductive tract infection (RTI)/STI programmes 
(PGT) (see Box 2.1) (35). The PGT, along with a 
number of other guidelines and tools, are available 
Box 2.1 
Programme guidance tool for reproductive tract infection/sexually transmitted infection programmes
The PGT facilitates an action-oriented process that can be used by decision-makers to set goals and 
directions and to prioritize interventions for addressing the problem of RTIs, including STIs. It takes 
into account the full range of contextual factors that can influence the ability of a health system to set 
priorities and deliver effective interventions, recognizing that appropriate decisions about policy and 
programme development should not only be based on disease epidemiology. The PGT recognizes the 
importance of relationships between the community, service clients, the service-delivery system, and 
the mix of interventions and services provided, taking into account how these interactions are influ-
enced by the broader sociocultural, economic and political context.
The PGT approach consists of 10 steps. The first eight steps amount to a strategic assessment of the 
current situation, on the basis of which strategic recommendations can be made. In step 9, the strate-
gic recommendations are implemented, and in step 10, those recommendations found to be effective 
are implemented on an expanded scale.
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should be integrated into existing data-
monitoring systems;
•	 regular collection and analysis of monitoring 
reports at all levels, with prompt feedback to 
programmes;
•	 development of sustainable mechanisms for 
providing ongoing support for in-country 
monitoring and evaluation of the adverse 
outcomes of pregnancy that result from syphilis 
infection.
Indicators and targets for the elimination of 
mother-to-child transmission of syphilis
Extensive consultations with a wide range of 
stakeholders have identified a limited number of 
indicators and targets to measure progress towards 
the goal of eliminating MTCT of syphilis, which can 
be feasibly incorporated into existing maternal, 
newborn and child health data systems (36). These 
include core indicators from WHO-recommended 
indicators for measuring universal access to 
reproductive health, as well as universal access to 
HIV interventions; impact indicators (congenital 
syphilis rates and the proportion of stillbirths 
attributable to syphilis in the mother); and a 
summary process indicator to estimate overall 
programme effectiveness. Furthermore, additional 
indicators may be necessary at the global, regional 
and national level, to provide a more comprehensive 
picture of initiative progress. Indicators are 
summarized in Box 2.2.
At the regional level, monitoring and evaluation 
data will enable countries with similar policy- and 
systems-level issues (e.g. distribution; health 
services coverage; surveillance and data systems; 
maternal, newborn and child health programme 
integration) to learn from each other.
At the global level, impact indicators will be used to 
monitor global programme impact, while the tools 
developed and lessons learnt through this initiative 
will contribute to scale-up in other countries in the 
future.
A broad range of activities are planned to monitor 
and evaluate the initiative, including:
•	 global collaboration with stakeholders to assist 
initiative partners in defining how indicators 
should be measured;
•	 development of tools to assist with collection 
of high-quality data, analysis that provides 
informative data to guide the programme, and 
dissemination of findings;
•	 regional consultations to define criteria and 
processes for validation of elimination of MTCT 
of both syphilis and HIV;
•	 national-level collaborative efforts to 
adapt existing national indicators to WHO 
recommendations where possible, outline 
definitive plans for monitoring and evaluation of 
MTCT of syphilis, and determine how indicators 
Box 2.2 
Indicators for the elimination of mother-to-child transmission of syphilis
Core process indicators – routine
Testing of ANC attendees for syphilis at first visit (global target >90% by 2015)
Positive syphilis serology in pregnant women (country-specific target)
Treatment of syphilis-seropositive pregnant women (global target >90% by 2015)
Additional indicators – as able 
Congenital syphilis rate (country- or region-specific target)
Estimated proportion of all syphilis-infected pregnant women who receive treatment by 24 weeks’ 
gestation (proposed target > 80%)
Proportion of stillbirths attributable to syphilis in the mother (proposed target <2%)
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Staff of the Department of HIV/AIDS collaborate 
with other UN agencies, ministries of health, 
development agencies, NGOs, health-services 
providers, health-care institutions, people living with 
HIV and other partners. The aim is to strengthen 
all aspects of the health sector, in order to deliver 
much-needed HIV services. WHO provides technical 
support and develops evidence-based norms and 
standards to help transform the goal of universal 
access to HIV care into a reality. An important 
aspect of universal access to HIV is to strengthen 
and expand health systems, including those for 
prevention and treatment of MTCT of syphilis.
WHO will manage the technical, programmatic and 
resource-building functions of the initiative. It will 
also appoint seven full-time staff at the global and 
regional level: a programme director, a laboratory 
quality assurance/procurement officer, an advocacy/
communications/fundraising officer, an assistant/
fiscal programme officer and three regional officers. 
Funds channelled through WHO would also be 
used at the global, regional and country levels to 
promote advocacy, strengthen policy, develop 
guidelines, scale up programmes, and support 
essential research to support elimination of MTCT 
of syphilis. Funds channelled through WHO are not 
intended for routine programme costs.
United Nations agency partners
The United Nations Population Fund (UNFPA) is an 
international development agency that promotes 
the right of every woman, man and child to enjoy 
a life of health and equal opportunity. UNFPA 
supports countries in using population data for 
policies and programmes to reduce poverty and to 
ensure that every pregnancy is wanted, every birth 
is safe, every young person is free of HIV/AIDS, and 
every girl and woman is treated with dignity and 
respect. For the initiative for the elimination of MTCT 
of syphilis, UNFPA plans to support introductory 
activities, implementation and upscaling, as well 
as capacity building and logistics management. In 
addition, UNFPA can facilitate pooled procurement 
and support countries to integrate adequate 
programmes in their national budget.
2.3 Key initiative partners 
National-level country teams
In-country activities for intensified support 
countries will be led by a programme coordinator 
working with a country team, made up of key 
stakeholders such as representatives from involved 
health programmes (maternal and child health, 
STI/HIV etc.), WHO country offices, representatives 
of civil society, representatives of primary 
stakeholder groups, donors, multilaterals, bilaterals, 
nongovernmental organizations (NGOs), research 
investigators and communications specialists.
The World Health Organization
The WHO Department of Reproductive Health 
and Research (RHR), with the assistance of the 
Departments of Maternal, Child and Adolescent 
Health (MCA) and HIV/AIDS, will coordinate 
global leadership and implementation of the 
initiative, provide technical support, and promote 
improvement of the evidence base for interventions. 
In addition, WHO regional advisers covering one or 
more of the areas of STI, HIV, reproductive health 
and MCH will provide similar functions at the 
regional level.
The mission of RHR is to help people to lead 
healthy sexual and reproductive lives. In pursuit 
of this mission, the department endeavours to 
strengthen the capacity of countries to enable 
people to promote and protect their own sexual and 
reproductive health and that of their partners, and 
to have access to, and receive, high-quality sexual 
and reproductive health services when needed.
MCA works to strengthen WHO capacity to support 
countries’ efforts to improve maternal, newborn 
and child health and reduce maternal, perinatal 
and child mortality. The department aims to 
reinforce advocacy, technical support, monitoring 
and evaluation, and partnerships in countries, to 
ensure that WHO can provide the most up-to-date 
information and guidance on maternal, newborn 
and child health, including issues related to MTCT of 
syphilis.
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provide technical support for the surveillance, 
monitoring and evaluation framework for the global 
initiative, as well as quality assurance of laboratory 
and health services.
Battling Against Syphilis – a Team Approach 
(BASTA)
An informal collaboration of key partners interested 
in eliminating MTCT of syphilis was created by WHO 
and CDC approximately 5 years ago, called “BASTA”: 
Battling Against Syphilis – a Team Approach. There 
are over 100 BASTA collaborators, who share ideas 
and information on efforts to eliminate MTCT of 
syphilis. BASTA collaborators work around the world 
in bilaterals, NGOs, academic centres, professional 
organizations and civil society (see Appendix 4). 
BASTA has been instrumental in the development of 
the investment case and research agenda outlined 
in this document, and has promoted and supported 
collaborative efforts, including dissemination 
of information (publications, symposium, etc.), 
development of tools, research in key areas, 
provision of technical expertise to countries, and 
integration of elimination of MTCT of syphilis into 
their respective work agendas.
In March 2012, several BASTA collaborators created 
the Global Congenital Syphilis Partnership, hosted 
in the London School of Hygiene and Tropical 
Medicine. WHO looks forward to collaborating with 
the newly formed partnership, in particular to:
•	 heighten public and professional awareness, and 
sense of urgency, on maternal syphilis and MTCT 
of infection;
•	 mobilize global commitment and action to scale 
up knowledge transfer and capacity building to 
accelerate the elimination of MTCT of syphilis;
•	 optimize the use of available tools in the fight 
against MTCT of syphilis, and enhance delivery 
of syphilis diagnosis and treatment, especially in 
pregnant women. 
2.4 Management structure
WHO will coordinate the activities of each of the 
main partners involved in the initiative, as well 
The United Nations Children’s Fund (UNICEF), is the 
leading UN agency tasked to advocate for children. 
The heart of UNICEF’s work is in the field. Each 
country office carries out UNICEF’s mission through 
a unique programme of cooperation developed 
with the host government. Regional offices guide 
this work and provide technical assistance to 
country offices as needed. For the initiative for the 
elimination of MTCT of syphilis, UNICEF plans to 
support implementation and scale-up, as well as 
logistics and supplies.
The Joint United Nations Programme on HIV/AIDS 
(UNAIDS) is an innovative joint venture of the UN 
family, bringing together the efforts and resources 
of 10 UN system organizations in the AIDS response, 
to help the world prevent new HIV infections, care 
for people living with HIV, and mitigate the impact 
of the epidemic. The UNAIDS Secretariat works on 
the ground in more than 80 countries worldwide. 
Coherent action on AIDS by the UN system is 
coordinated in countries through the UN theme 
groups, and the joint programmes on AIDS. For the 
initiative for the elimination of MTCT of syphilis, 
UNAIDS plans to support advocacy on HIV-infected 
women, and linkages between HIV programmes, STI 
control programmes and sexual and reproductive 
health programmes.
United States of America Centers for Disease 
Control and Prevention
The Centers for Disease Control and Prevention 
(CDC) is the agency of the Department of Health 
and Human Services in the USA that focuses on 
public health and prevention. With a mission of 
collaborating to create the expertise, information 
and tools that people and communities need to 
protect their health, CDC works with global partners 
on specific global goals, including public health 
programmes aimed at reducing infant mortality. 
The Division of STD [Sexually Transmitted Disease] 
Prevention (DSTDP) in the National Center for 
HIV, Viral Hepatitis, STD and TB Prevention is 
CDC’s component agency supporting the global 
elimination of MTCT of syphilis. In the initiative 
for the elimination of MTCT of syphilis, DSTDP will 
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The core team will be composed of the WHO 
programme director, the regional programme 
officers (who will represent the intensified support 
country teams), the advocacy/communication/ 
fundraising officer, the laboratory quality assurance 
and procurement officer, and the financial 
management/administrative officer. The core team 
will report to the steering committee. The steering 
committee will be composed of the core team, as 
well as representatives of key UN partner agencies 
and other partners. The core team and the steering 
committee will need to be financially and logistically 
supported to achieve their mandates.
The role of the core team is to ensure coordination 
at all levels, in both intensified and general support 
countries:
•	 the programme director, based at WHO 
headquarters, will act on behalf of the steering 
committee to oversee the core team. This person 
will have primary responsibility for programme 
implementation, coordination of the programme 
and with partners, and achievement of 
as donor inputs and reporting requirements, and 
a global fundraising and advocacy campaign. 
Initiative partners will also be responsible 
for disseminating outputs (e.g. at national 
and international meetings), updating and 
reviewing existing guidelines, and disseminating 
recommendations to both intensified and general 
support countries.
These activities will be undertaken through a close 
collaboration between staff at global and regional 
levels who are dedicated to work on this elimination 
initiative, as well as staff working for allied 
programmes that are fundamental to the success 
of the initiative (e.g. staff working on maternal child 
health, and those working on STI control and HIV 
programmes).
Fig. 2.1 is a graphical representation of the overall 
management structure for implementing the 
initiative. The roles and responsibilities of the major 
players are described next.
Fig. 2.1 
Management structure of the initiative for the global elimination of mother-to-child transmission of 
syphilis
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•	 a financial and administrative officer will be 
hired and deployed at WHO headquarters. Her/
his primary responsibilities will be to lead the 
financial management technical group, develop 
a fiscal reporting system that will be used by all 
funds’ recipients, and track all funds held and 
deployed in the field for specific activities;
The role of the steering committee will be to:
•	 determine the overall strategic plan for the 
global initiative;
•	 direct policy and guide the overall trajectory of 
the initiative;
•	 review narrative and financial reports;
•	 be responsible for the overall accountability of 
the resources;
•	 champion the global elimination initiative in the 
international arena;
•	 review and approve the annual programme 
of work to ensure that activities in intensified 
support countries are in line with the vision and 
goals;
•	 review, discuss and provide input on funding 
proposals;
•	 support intensified-support-country-level 
programme coordinators to develop national 
plans;
•	 coordinate overall monitoring and evaluation;
•	 review annual programme results and overall 
progress towards achievement of the global 
elimination initiative.
objectives. In addition, the programme director 
will oversee operational research, monitoring 
and evaluation activities;
•	 regional officers will be placed in three of the 
WHO regions to aid in full implementation 
of activities, and to promote the initiative to 
intensified and general support countries in their 
region. These regional officers will also serve as 
technical officers, responsible for monitoring and 
evaluation for their region. The regional officers 
will help to coordinate activities across the range 
of programmes involved in delivering the goals 
of the initiative (ANC, STI control, prevention of 
MTCT of HIV, etc.).
•	 an advocacy, communication and fundraising 
officer will be hired and deployed at 
WHO headquarters to lead an advocacy/
communication/fundraising technical group. 
This person will have primary responsibility 
for advocacy, donor coordination, and 
communication. This officer will provide 
fundraising and strategic guidance to fund 
and launch the initiative, and ensure active 
communication between the core team, the 
steering committee and other partners;
•	 a laboratory quality assurance and 
procurement officer will be hired and deployed 
at WHO headquarters to work closely with 
the WHO Essential Medicines Programme 
Department to develop and support global, 
regional and national laboratory quality 
assurance systems, support the steps necessary 
for prequalification of diagnostics, and work to 
improve the stability of procurement of essential 
diagnostics and medications by countries;
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•	 health-system initiatives to promote integrated 
comprehensive sexual and reproductive health 
care.
In addition, it is recognized that the elimination of 
MTCT of syphilis is likely to be more achievable if 
syphilis screening and treatment activities are also 
included in the existing health initiatives (such as 
elimination of MTCT of HIV). Therefore, combining 
syphilis interventions with basic ANC programmes 
as well as prevention of MTCT programmes makes 
medical, economic and political sense (37).
Recent efforts by WHO have simplified ANC and 
provided norms to encourage health-care workers 
to emphasize a few essential components of care 
(38, 39). This initiative will build on these norms and 
provide support for health-services evaluation that 
can jump-start feasible and efficient management 
and data-collection systems around integrated ANC. 
It will also build capacity that supports all ANC – 
even beyond elimination of MTCT of syphilis.
3.2 Supporting country-level impact 
through global coordination
The initiative outlined in this investment case does 
seek a limited amount of funding for country-
level programme implementation. Countries 
identified for intensified support – which all have 
a high burden of MTCT of syphilis – will already be 
committed to syphilis elimination and have ANC 
programmes in place, backed by other sources 
of funding. They also may already be receiving 
substantial financial support for HIV, tuberculosis 
and malaria prevention (e.g. The Global Fund to 
Fight AIDS, Tuberculosis and Malaria). It is hoped 
that the funding for country-level programme 
implementation from this initiative can be used to 
integrate components of elimination of MTCT of 
syphilis into existing ministry of health programmes 
to ensure sustainable and strengthened health 
systems.
3. The strength of this initiative
3.1 Leveraging existing investments in 
maternal and child health
This initiative will build on investments in maternal 
and child health services that have already been 
made by governments and donors in developing 
countries. It works through, and therefore inevitably 
strengthens, national health systems, particularly 
antenatal and other reproductive and sexual health-
care programmes.
Today, over three quarters of all pregnant women 
receive at least one ANC visit (24). This is an 
indication that programmes and infrastructure exist 
in many countries, and that there is widespread 
awareness and acceptance of ANC by pregnant 
women.
This initiative will help to maximize the ability of 
these existing programmes to improve maternal 
health and reduce infant mortality. It will harness 
new technological developments and strengthen 
existing services to promote early ANC for all 
pregnant women and ensure that they receive 
testing (and, where indicated) treatment for syphilis 
at their first antenatal clinic visit. We support a 
simple, integrated and effective ANC approach that 
can provide sustainable services within the broad 
context of strengthening primary health care, while 
concentrating on this prevalent, high-burden and 
neglected disease.
The focus on early access to services and the quality 
of comprehensive ANC will strengthen synergistic 
efforts to reduce the burdens of HIV, malaria, 
tetanus, parasites and accompanying anaemia, as 
well as MTCT of syphilis. As such, it will promote 
synergies by supporting:
•	 ongoing community mobilization programmes 
(to encourage women to seek and access ANC 
early in pregnancy);
•	 existing efforts to improve the quality of ANC;
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Adverse pregnancy outcomes are the critical 
public health problem associated with maternal 
syphilis infection. The congenital syphilis case 
rate is the most widely recognized measure of the 
impact of elimination efforts. Unfortunately, global 
surveillance of MTCT of syphilis is challenging, since 
there is no single test or combination of laboratory 
tests to definitively diagnose an infected infant. As a 
result, a case definition for congenital syphilis must 
rely on clinical history and examination. Thus, case 
definitions vary widely by country, and a globally 
accepted surveillance case definition is still under 
development.
Maternal syphilis infection also contributes 
substantially to rates of stillbirth, though this 
outcome is often underreported in many settings. 
Nonetheless, despite the current lack of universal 
measuring of stillbirth rates, we are proposing this 
as a potentially sensitive and specific measure of the 
impact of  elimination of MTCT of syphilis efforts. 
Promoting the monitoring and measurement of 
stillbirth rates will not only allow us to assess the 
impact of this initiative, it will also help support 
and strengthen reproductive health surveillance 
programmes more generally.
In addition, discussions at a regional and global 
level are under way to identify criteria and processes 
for validation of elimination. Given that there are 
several countries that may actually have eliminated 
MTCT of syphilis already, establishment of such a 
process is critical for recognizing this achievement, 
as well as is providing recommendations on how 
to maintain elimination. In addition, validation may 
be an important motivator to engage countries 
in elimination, and encourage countries to go 
the last distance to provide services for even the 
most difficult-to-reach populations. The validation 
process is being undertaken jointly with the global 
programme to eliminate MTCT of HIV, given the 
commonalities of the initiatives and programme 
platforms.
Through a series of global, regional and national 
consultations, countries have indicated that they 
need technical assistance to learn how to integrate 
and scale up syphilis screening and treatment 
into existing programmes and to monitor these 
interventions. Countries have also indicated a need 
to bring more attention to the burden of MTCT of 
syphilis at all levels, which will help to prioritize the 
issue on national and international health agendas.
To this end, the initiative will mobilize regional and 
global stakeholders into a network that can deliver 
rapid, targeted technical assistance to intensified 
support countries to work alongside national 
counterparts to fully and effectively integrate 
syphilis interventions into existing ANC and PMTCT 
of HIV programmes. This initiative will also dedicate 
human and financial resources at the regional and 
global levels, to work with national colleagues 
to monitor the scale-up of country-level syphilis-
elimination interventions. Although prioritization of 
resources will be aimed at the intensified support 
countries, it is anticipated that the network created 
by the investment case will also be able to provide 
general support for other countries as needed.
3.3 Investing in surveillance, 
monitoring and evaluation
Previous WHO/CDC technical consultations have 
recommended the development of a monitoring 
system based upon already-established national 
systems for ANC. Such an approach supports 
overall health-systems infrastructure and a quality 
package of antenatal and perinatal preventive 
services. Through these consultations, a list of the 
critical benchmarks was proposed for appropriate 
local programmes within each country, with 
annual measurement recommended. Some have 
already been tried out in local settings; others need 
further evaluation for feasibility. Investment in 
this initiative will support local and national-level 
research needed to solidify the critical programme 
benchmarks that will be adopted globally.
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costing, too, for example (42). The next step for 
the South-East Asia and Western Pacific Regions, 
however, is to identify resources to work with 
countries to establish integrated policies and ensure 
clinical guidelines and monitoring systems support 
these policies. The African Region is currently 
developing a regional framework for elimination 
of MTCT of HIV, which includes the strengthening 
of related MCH services such as the elimination of 
MTCT of syphilis (22).
In all of these regions, scaling-up of use of point-
of-care rapid testing has been identified as critical 
for expanding testing to pregnant women seen 
in peripheral health settings. All regions have 
also expressed the need to establish criteria and 
a process for validation of elimination that is 
integrated with that for MTCT of HIV. Thus, it is 
crucial that WHO works closely with the regions to 
facilitate interregional collaboration and establish 
credible, sustainable processes for validation of 
elimination globally and regionally.
There is also much work being done in the area of 
improving best practices for syphilis testing. WHO 
and other partners also support the elimination of 
MTCT of syphilis through work on improved rapid 
syphilis diagnostic tests applicable for resource-
limited settings, including development of rapid 
point-of-care tests that use whole blood (e.g. finger 
prick) samples that can be used by health-care 
3.4 Implementing knowledge and best 
practices
This investment case represents a new direction for 
WHO and its partners in their goal of eliminating 
MTCT of syphilis, but it also builds upon many years 
of experience and evidence gathering. In recent 
years, several state-of-the-art reviews on maternal 
and congenital syphilis (MTCT of syphilis) have been 
published to highlight the problem and advocate 
action for its elimination (40). These reviews provide 
empirical evidence of the burden of MTCT of 
syphilis globally and information on experiences of 
programmes attempting to intervene and address 
this burden.
At regional level, some longstanding efforts 
to eliminate MTCT of syphilis have made great 
progress, but still need assistance to reach the last 
distance. For example, the Pan American Health 
Organization (PAHO) has developed several tools to 
assist countries with development of policy, clinical 
guidance, and monitoring and evaluation (41). 
See also Box 3.1. However, PAHO needs additional 
support to provide technical assistance to countries 
and strengthen monitoring and evaluation systems. 
In the WHO South-East Asia and Western Pacific 
Regions, the Asia Pacific Task Force (which includes 
WHO, UNAIDS, UNICEF and UNFPA) has also 
made great strides in outlining a strategy for dual 
elimination of MTCT of HIV and syphilis, including 
indicators for monitoring and evaluation, and a 
Box 3.1 
PAHO Regional Initiative to Eliminate Vertical Transmission of HIV and Syphilis
Since 1995 PAHO has strived to eliminate MTCT of syphilis in the Americas.  In 2009, PAHO countries, 
in collaboration with WHO, UNICEF and others, agreed to a goal of dual elimination MTCT of HIV and 
congenital syphilis (MTCT of syphilis) by 2015. 
The PAHO initiative aims to reduce MTCT of HIV to 2% or less and reduce congenital syphilis (including 
stillbirths) to 0.5 cases per 1000 live births or fewer. In addition, the regional initiative seeks to ensure 
that at least 95% of pregnant women receive early ANC that includes screening for both HIV and 
syphilis.
The initiative intends to attain these goals through scaling up services for primary prevention of HIV 
and syphilis and strengthening of health systems for maternal and child health services, surveillance, 
monitoring and evaluation.
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providers at the lowest level of health care. However, 
the syphilis point-of-care tests currently available 
commercially are treponemal, meaning that they 
can only measure a lifetime history of syphilis 
exposure. Thus, additional support is needed for 
WHO to encourage development and field testing 
of nontreponemal tests to measure current syphilis 
infection, as well as bundled diagnostics that allow 
concomitant testing for syphilis, HIV, hepatitis B, 
etc. The development of such tests is critical for 
minimizing the burden of primary care health 
workers to provide quality, integrated care.
These are just a few examples of the efforts and 
advances that this initiative will build upon and 
help to advance. Now – more than ever before – is 
the right time to address MTCT of syphilis with 
a large-scale, global initiative. Investment today 
will contribute significantly to maternal and child 
health improvements around the world, including 
achievement of the MDGs.
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We assumed, based on published evidence, 
that treatment was 90% effective, that coverage 
depends on the current proportion tested and 
treated: 70–95% of women are in antenatal care 
(ANC), of whom 80–90% are tested, and 90–95% 
of test-positive women are treated. The adverse 
outcomes averted were stillbirth/early fetal losses, 
20.9%; early neonatal deaths, 9.3%; prematurity 
or low birth weight, 5.8%; and infants with clinical 
evidence of syphilis, 15.5%. These rates derived from 
a systematic search and abstraction of studies of 
untreated syphilis.
We also assumed that treating syphilis reduced 
the horizontal spread of syphilis and had a modest 
(20%) effect in reducing the effect of syphilis 
as a cofactor for transmission of HIV. The DALYs 
averted per adverse event averted were derived 
from estimates in the Global burden of disease (44). 
All long-term outcomes were discounted, but 
the analysis did not discount over the 4 years of 
initiative implementation. Further details (including 
sensitivity analyses) are available in a technical 
supplement on request.
Results
We found that controlling mother-to-child 
transmission (MTCT) of syphilis appears to save 
more than it costs in four of the eight country 
scenarios we examined. The initiative was cost 
saving in these four countries, even when excluding 
the benefits of reducing the horizontal spread of 
syphilis, and excluding syphilis-attributable HIV. 
Results by scenario are presented Table 1.4.
Appendix 1: economic analysis and disability-adjusted life 
years calculations
Methods
We conducted an illustrative analysis of the 4-year 
cost, health impact, and cost-effectiveness of 
syphilis programmes in eight hypothetical country 
case scenarios. These country scenarios vary in 
terms of current syphilis testing and treatment 
coverage of all pregnant women (high (70%) or low 
(20%)), syphilis ANC prevalence (high (3%) or low 
(0.5%)), and country cost of health services (high or 
low, based on WHO CHOICE (Choosing Interventions 
that are Cost Effective) unit cost data).
The cost analysis assessed the cost of the 
intervention – implementing expanded testing 
and treatment of syphilis in pregnancy. The health-
impact analysis translated increased testing and 
treatment into adverse outcomes averted, and the 
associated averted disability adjusted life years 
(DALYs). The cost-effectiveness analysis adjusted for 
offsetting savings due to averted adverse outcomes, 
and if there was still a net cost, that cost was divided 
by the DALYs averted. The key inputs, assumptions 
and rationale for the calculations of the costs and 
DALYS results are presented in Table A.1.
Our key cost assumption concerned the cost of 
implementing testing and treatment. This was 
derived from several sources. Key commodity prices 
(e.g. rapid plasma reagin (RPR) tests and penicillin 
doses) were determined from the World Health 
Organization (WHO) bulk procurement system, with 
allowances for delivery costs. The costs of labour 
and of adverse outcomes were derived from an 
analysis using South Africa costs (43). The overall 
cost of testing was US$1.83–2.30 per woman and 
of treatment with three doses of penicillin was 
US$3.72–3.79.
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Table A.1 
Inputs and assumptions for illustrative analysis of the 4-year cost, health impact, and cost-effectiveness 
of syphilis programmes in 8 hypothetical country case scenarios 
Parameter Value or rangea Source/notes
Adverse event rate 
Stillbirth/early fetal loss 0.209 Synthesis of research findings (Table 1.1)
Early neonatal death 0.093 Synthesis of research findings (Table 1.1)
Infected infant 0.155 Synthesis of research findings (Table 1.1)
Prematurity or low birth weight 0.058 Synthesis of research findings (Table 1.1)
Costs, US$
Stillbirth / spontaneous abortion (0)–(1) Per Rydzak and Goldie 2008 (43), delivery 
of healthy infant = US$58
Perinatal death 893–3571 Per Rydzak and Goldie, 2008 (43), adjust-
ed per WHO CHOICE inpatient unit costs
Infected infant 182–243 Per Blandford et al, 2007 (27), and Rydzak 
and Goldie, 2008 (43), includes adjust-
ment for 30% discovery rate, adjusted per 
WHO CHOICE outpatient unit costs
Prematurity or low birth weight 366–1464 Per Rydzak and Goldie, 2008 (43), adjust-
ed per WHO CHOICE inpatient unit costs 
Primary syphilis 15 Estimate based on single visit, test, peni-
cillin
Secondary and early latent syphilis 15 Same as primary
Late latent and tertiary syphilis 500–2000 Based on Chesson et al, 2004 (45) esti-
mates for USA,, adjusted for lower price 
and lower incidental treatment in devel-
oping countries and WHO CHOICE inpa-
tient unit costs
HIV infection 6500 (28) 
Syphilis test, test + labour/supplies 1.83–2.30 Based on WHO Bulk Procurement esti-
mates (WHO, unpublished data, 2012)
Course of benzathine benzylpenicillin (3 
doses)
3.72–3.79 Based on WHO Bulk Procurement esti-
mates (WHO, unpublished data, 2012)
a Values in parentheses indicate negative values.
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Appendix 2: proposed budget for the initiative for the global 
elimination of mother-to-child transmission of syphilis
5-year budget summary in US$ Year 1 Year 2 Year 3 Year 4 4-year total
Global support  
1 P5, programme director, Geneva 330 000 330 000 330 000 330 000 1 320 000
1 P4, laboratory quality assurance 
and procurement officer, Geneva
285 000 285 000 285 000 285 000 1 140 000
1 P3, advocacy, communications, 
and fundraising officer, Geneva
230 000 230 000 230 000 230 000 920 000
1 G5, financial and administrative 
officer, Geneva
170 000 170 000 170 000 170 000 680 000
Advocacy efforts 50 000 50 000 50 000 50 000 200 000
Technical and strategic support to 
regions and countries
100 000 100 000 100 000 100 000 400 000
International meetings 150 000 150 000 150 000 150 000 600 000
Subtotal global support 1 315 000 1 315 000 1 315 000 1 315 000 5 260 000
Regional support  
1 P3, regional officer 230 000 230 000 230 000 230 000 920 000
1 P3, regional officer 230 000 230 000 230 000 230 000 920 000
1 P3, regional officer 230 000 230 000 230 000 230 000 920 000
Technical and strategic support to 
countries
150 000 150 000 150 000 150 000 600 000
Regional meetings 120 000 120 000 120 000 120 000 480 000
Subtotal regional support 960 000 960 000 960 000 960 000 3 840 000
Country support  
Programme supervision 400 000 400 000 400 000 400 000 1 600 000
Advocacy and policy development 150 000 150 000 150 000 150 000 600 000
Evidence-based guideline develop-
ment, training and dissemination
300 000 300 000 300 000 300 000 1 200 000
Evaluation of indicators and impact 200 000 200 000 200 000 200 000 800 000
Strengthening of laboratory quality 
assurance and test procurement
300 000 300 000 300 000 300 000 1 200 000
Policy, implementation barriers and 
operational research
200 000 200 000 200 000 600 000
Research on social sciences or part-
ner management
 150 000 150 000  300 000
Subtotal country support 1 550 000 1 700 000 1 700 000 1 350 000 6 300 000
Subtotal     15 400 000
Administrative support (13%)     2 002 000
Grand total 3 825 000 3 975 000 3 975 000 3 625 000 17 402 000
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Nine steps for developing a scaling-up 
strategy
•	 Description: a guide for programme managers 
and technical support agencies to facilitate 
systematic planning for scaling up
•	 Available at: http://www.expandnet.net/
PDFs/ExpandNet-WHO%20Nine%20Step%20
Guide%20published.pdf 
Clinical guidelines
Sexually transmitted and other reproductive 
tract infections: a guide to essential practice
•	 Description: a reference manual developed for 
health-care workers and programme managers 
on STI/reproductive tract infection (RTI) control 
and management in reproductive health settings 
(family planning and maternal and child health 
clinics as well as primary health care)
•	 Available at: http://www.who.int/
reproductivehealth/publications/
rtis/9241592656/en/index.html
Standards for maternal and neonatal care: 
prevention of mother-to-child transmission of 
syphilis
•	 Description: World Health Organization (WHO) 
recommendations on essential care for women 
and their babies
•	 Available at: http://www.who.int/
reproductivehealth/publications/maternal_
perinatal_health/prevention_mtct_syphilis.pdf
Regional and national treatment/
management guidelines
•	 Description: Expert recommendations on clinical 
management of syphilis and MTCT of syphilis 
that is locally relevant. Most nations have this 
information in national treatment guidelines
The use of rapid syphilis tests
•	 Description: information for health-care workers 
and laboratory technicians on the use and 
interpretation of rapid plasma reagin (RPR) and 
point-of-care rapid treponemal syphilis tests
•	 Available at: http://www.who.int/
reproductivehealth/publications/rtis/TDR_
SDI_06_1/en/index.html
Appendix 3: list of tools available for country-level 
activities
Advocacy and programme tools
The global elimination of congenital syphilis: 
rationale and strategy for action
•	 Description: document outlining strategies for 
elimination that can be used for advocacy and 
implementation
•	 Available at: http://www.who.int/
reproductivehealth/publications/
rtis/9789241595858/en/index.html
A strategic approach to strengthening control 
of reproductive tract and sexually transmitted 
infections
•	 Description: programme manager tool based 
on stepwise and comprehensive approach to 
integrate interventions in existing programmes 
or to strengthen health programmes
•	 Available at: http://www.who.int/
reproductivehealth/publications/
rtis/9789241598569/en/index.html
Methods for surveillance and monitoring 
of congenital syphilis elimination within 
existing systems
•	 Description: tool for regional and national 
programme managers on the core indicators 
for elimination of congenital syphilis (MTCT of 
syphilis) efforts that are harmonized with and 
integrated into existing data-collection systems
•	 Available at: http://www.who.int/
reproductivehealth/publications/
rtis/9789241503020/en/index.html
Global strategy for the prevention and control 
of STIs: 2006–2015. Breaking the chain of 
transmission
•	 Description: a technical and advocacy document 
intended to offer guidance on how to improve 
sexually transmitted infection (STI) control 
programmes
•	 Available at: http://www.who.int/
reproductivehealth/publications/
rtis/9789241563475/en/
30
Investment case for eliminating mother-to-child transmission of syphilis
National Center for STD Control, China
National Coalition of STD, United States (NCSD)
Norwegian Agency for Development Cooperation 
(Norad)
PATH
The Population Council
Public Health Agency of Canada
United Nations Population Fund (UNFPA)
United Nations Children’s Fund (UNICEF)
United States Office of the US Global AIDS 
Coordinator (OGAC)
United States Agency for International Development 
(USAID)
Universidad Peruana Cayetano Heredia
University of Alabama Birmingham
University of Antwerp
University of Barcelona
University of California Los Angeles
University of California San Francisco
University College London
University of Gent
University of North Carolina
University of Victoria
University of Washington
Washington University in St Louis
Appendix 4: Battling Syphilis – a Team Approach (BASTA) 
participant affiliations
Alberta Health Services of Canada
Amsterdam institute for Global Health and 
Development (AIGHD)
Brazil Ministry of Health
CDC Foundation
Centers for Disease Control and Prevention, United 
States (CDC)
Centro Internacional de Entrenamiento e 
Investigaciones Médicas (CIDEIM)
Centro Latinoamericano de Perinatologia (CLAP)
Children’s Investment Fund Foundation (CIFF)
Cornell University
Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)
Engenderhealth
FHI360
The Global Fund
Harvard University
Health Alliance International
Imperial College London
Institute of Development Studies
Jhpiego
Johns Hopkins University
Joint United Nations Programme on HIV/AIDS 
(UNAIDS)
London School of Hygiene and Tropical Medicine 
(LSHTM)
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